Warner Chilcott announced the launch of a 200mg dosage strength for Doryx (doxycycline hyclate) delayed-release tablets.
Doryx is a tetracycline antibiotic indicated as adjunct treatment in severe acne, the treatment of tetracycline-susceptible infections including respiratory, genitourinary, rickettsial, trachoma, and for postexposure prophylaxis and treatment of anthrax.
Doryx inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
It has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria.
Doryx 200mg delayed-release tablets are available in 60-count bottles. Doryx is already available in 80mg, 100mg, and 150mg dosage strength tablets.
For more information call (800) 521-8813 or visit www.wcrx.com.